Document Detail

Treatment of paraneoplastic cerebellar degeneration.
MedLine Citation:
PMID:  23315179     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Paraneoplastic cerebellar degeneration is an uncommon autoimmune disorder characterized clinically by progressive, ultimately incapacitating ataxia and pathologically by destruction of cerebellar Purkinje cells, with variable loss of other cell populations. The disorder is most commonly associated with gynecological and breast carcinomas, small cell carcinoma of the lung, and Hodgkin's disease and in most cases comes on prior to identification of the underlying neoplasm. The hallmark of paraneoplastic cerebellar degeneration is the presence of an immune response reactive with intracellular proteins of Purkinje or other neurons or, less commonly, against neuronal surface antigens. Evidence-based treatment strategies for paraneoplastic cerebellar degeneration do not exist; and approaches to therapy are thus speculative. Diagnosis and treatment of the underlying neoplasm is critical, and characterization of the antibody response involved may assist in tumor diagnosis. Most investigators have initiated treatment with corticosteroids, plasma exchange, or intravenous immunoglobulin G. Cyclophosphamide, tacrolimus, rituximab, or possibly mycophenolate mofetil may warrant consideration in patients who fail to stabilize or improve on less aggressive therapies. Plasma exchange has been of questionable benefit when used alone but should be considered at initiation of treatment to achieve rapid lowering of circulating paraneoplastic autoantibodies. Because the course of illness is one of relentless neuronal destruction, time is of the essence in initiating treatment. Likelihood of clinical improvement in patients with longstanding symptoms and extensive neuronal loss is poor.
John E Greenlee
Related Documents :
21690129 - Mapping behavioural evolution onto brain evolution: the strategic roles of conserved or...
7976529 - Morphology of non-vascular intracerebral fluid spaces.
21736899 - Complementary activation of hippocampal-cortical subregions and immature neurons follow...
22099459 - Interaction between fez1 and disc1 in regulation of neuronal development and risk for s...
2271919 - Brains, bodies and metabolism.
20514209 - Mechanisms of brain signaling during sepsis.
4026679 - Auditory brain-stem response in determination of brain death.
1880549 - Mossy fiber synaptic reorganization induced by kindling: time course of development, pr...
16792289 - Classifying eeg and ecog signals without subject training for fast bci implementation: ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current treatment options in neurology     Volume:  15     ISSN:  1092-8480     ISO Abbreviation:  Curr Treat Options Neurol     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-03-29     Completed Date:  2013-04-01     Revised Date:  2013-07-25    
Medline Journal Info:
Nlm Unique ID:  9815940     Medline TA:  Curr Treat Options Neurol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  185-200     Citation Subset:  -    
Clinical Neuroscience Center, University of Utah, 175 North Medical Drive East, Salt Lake City, UT, 84132, USA,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  "He didn't say that thalassaemia might come up" - ?-thalassaemia carriers' experiences and attitudes...
Next Document:  Strict component positioning is necessary in hip resurfacing.